Glenmark Pharmaceuticals’ arm acquires, launches Acetylcysteine Injection

03 Mar 2025 Evaluate

Glenmark Pharmaceuticals’ US-based subsidiary -- Glenmark Pharmaceuticals Inc, USA has acquired and launched Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials. Glenmark’s Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials can be expected to have the same therapeutic effect as the listed drug product upon which the Agency relied as the basis of safety and effectiveness, Acetadote Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials of Cumberland Pharmaceuticals Inc. Glenmark acquired the ANDA for Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials from Aspen Pharma USA Inc.

According to IQVIATM sales data for the 12-month period ending January 2025, the Acetadote Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials market achieved annual sales of approximately $15.2 million.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

2015.70 5.75 (0.29%)
29-Dec-2025 10:56 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1721.05
Dr. Reddys Lab 1265.10
Cipla 1502.20
Zydus Lifesciences 905.55
Lupin 2099.55
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×